Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Generalisation from phase III clinical trials: survival, quality of life, and health economics.

Fayers PM, Hand DJ.

Lancet. 1997 Oct 4;350(9083):1025-7. No abstract available.

PMID:
9329528
2.

The costs of conducting clinical research.

Emanuel EJ, Schnipper LE, Kamin DY, Levinson J, Lichter AS.

J Clin Oncol. 2003 Nov 15;21(22):4145-50. Epub 2003 Oct 14.

PMID:
14559889
3.

Economic analysis of randomized, controlled trials.

Lyman GH.

Curr Oncol Rep. 2001 Sep;3(5):396-403.

PMID:
11489239
4.

Factors to consider when designing phase III clinical trials involving economic evaluations.

van Enckevort PJ, TenVergert EM, Kingma J, Koëter GH, Rutten FF.

Percept Mot Skills. 1999 Dec;89(3 Pt 2):1059-72. Review.

PMID:
10710753
5.

Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer.

Sacristán JA, Kennedy-Martin T, Rosell R, Cardenal F, Antón A, Lomas M, Alberola V, Massuti B, Carrato A, Minshall M.

Lung Cancer. 2000 May;28(2):97-107.

PMID:
10717327
6.

Cancer therapy and the randomized clinical trial: good medicine?

Kaufman D.

CA Cancer J Clin. 1994 Mar-Apr;44(2):109-14.

7.

Effect of a US National Institutes of Health programme of clinical trials on public health and costs.

Johnston SC, Rootenberg JD, Katrak S, Smith WS, Elkins JS.

Lancet. 2006 Apr 22;367(9519):1319-27. Review.

PMID:
16631910
8.

Quality of life and clinical trials in HIV infection.

Barker S, Tindall B, Carballo M.

Lancet. 1990 Apr 28;335(8696):1045. No abstract available.

PMID:
1970103
9.

Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials.

Bennett CL, George SL, Vose JM, Nemunaitis JJ, Armitage JL, Armitage JO, Gorin NC, Gulati SC.

Stem Cells. 1995 Jul;13(4):414-20.

PMID:
7549900
10.

Reliable evidence of safety and efficacy of elderly patients in randomized clinical trials still needed.

Crean SM, Reynolds MW, Dematto CA.

J Clin Oncol. 2007 Sep 1;25(25):4027-8; author reply 4028. No abstract available.

PMID:
17761994
11.

Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy.

Hornberger J, Chien R, Friedmann M, Han L, Shewade A, Satram-Hoang S, Reyes C.

Leuk Lymphoma. 2012 Dec;53(12):2371-7. doi: 10.3109/10428194.2012.694429. Epub 2012 Jun 12.

PMID:
22591119
12.

Clinical trials and tribulations. Spiraling costs threaten gridlock.

Malakoff D.

Science. 2008 Oct 10;322(5899):210-3. doi: 10.1126/science.322.5899.210. No abstract available.

PMID:
18845742
13.

Health Economics Unit achievements.

Crott R, Neymark N.

Eur J Cancer. 2002 Mar;38 Suppl 4:S147-50.

PMID:
11858982
14.

Economic analysis in phase III clinical cancer trials.

Bennett CL, Armitage JL, Buchner D, Gulati S.

Cancer Invest. 1994;12(3):336-42.

PMID:
8187012
15.

Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).

Brettschneider C, Lühmann D, Raspe H.

GMS Health Technol Assess. 2011 Feb 2;7:Doc01. doi: 10.3205/hta000092.

16.

Challenges in the design and conduct of phase III brain tumor therapy trials.

Perry JR, DeAngelis LM, Schold SC Jr, Burger PC, Brem H, Brown MT, Curran WJ, Scott CB, Prados MD, Kaplan R, Cairncross JG.

Neurology. 1997 Oct;49(4):912-7. Review. No abstract available.

PMID:
9339667
17.

Economic analysis during phase III clinical trials: who, what, when, where, and why?

Bennett CL, Westerman IL.

Oncology (Williston Park). 1995 Nov;9(11 Suppl):169-75. Review.

19.

Economic analyses of phase III cooperative cancer group clinical trials: are they feasible?

Bennett CL, Golub R, Waters TM, Tallman MS, Rowe JM.

Cancer Invest. 1997;15(3):227-36.

PMID:
9171857
20.

Statistical methodology of phase III cancer clinical trials: advances and future perspectives.

Sylvester R, Van Glabbeke M, Collette L, Suciu S, Baron B, Legrand C, Gorlia T, Collins G, Coens C, Declerck L, Therasse P.

Eur J Cancer. 2002 Mar;38 Suppl 4:S162-8.

PMID:
11858987

Supplemental Content

Support Center